Does the Alzheimer’s drug aducanumab work?
That was the central issue during an interview of Biogen’s head of research and development and chief medical officer, Dr. Al Sandrock, at the STAT Summit in Cambridge, Mass., late last month. Sandrock’s answer, in short, was undoubtedly yes.
“Here’s the decision that FDA is going to have to make,” Sandrock told STAT, when asked whether Biogen should run another confirmatory trial. “Do we believe there is enough evidence to approve it now? Or do we ask the company to do another trial, wait five years and how many people have to get demented in that time period?”
